Intra-CSF administration of chemotherapy medications

详细信息    查看全文

• 作者：Michael P. Gabay (2)
  Jigisha P. Thakkar (1)
  Joan M. Stachnik (2)
  Susan K. Woelich (24)
  J. Lee Villano (13) jvillano@uic.edu
• 关键词：Leptomeningeal carcinomatosis – ; Chemotherapy – ; Intrathecal – ; Neoplastic meningitis
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2012
• 出版时间：July 2012
• 年：2012
• 卷：70
• 期：1
• 页码：1-15
• 全文大小：261.9 KB
• 参考文献：1. Shapiro WR, Johanson CE, Boogerd W (2009) Treatment modalities for leptomeningeal metastases. Semin Oncol 36(4 Suppl 2):S46–S54
  2. Chamberlain MC (2008) Neoplastic meningitis. Oncologist 13(9):967–977
  3. Lombardi G, Zustovich F, Farina P et al (2011) Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist 16(8):1175–1188
  4. Siddiqui F, Marr L, Weissman DE (2009) Neoplastic meningitis #135. J Palliat Med 12(1):88–89
  5. Brastianos PK, Brastianos HC, Hsu W et al (2011) The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. J Neurooncol
  6. van Oostenbrugge RJ, Hopman AH, Ramaekers FC et al (1998) In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38(2–3):127–133
  7. Cibas ES, Malkin MG, Posner JB et al (1987) Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 88(5):570–577
  8. Biesterfeld S, Bernhard B, Bamborschke S et al (1993) DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluid. Acta Neuropathol 86(5):428–432
  9. van Oostenbrugge RJ, Hopman AH, Arends JW et al (1998) The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 51(3):906–908
  10. Glantz MJ, Cole BF, Glantz LK et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82(4):733–739
  11. Chamberlain MC, Kormanik PA, Glantz MJ (2001) A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 3(1):42–45
  12. Chamberlain MC (1998) Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37(3):271–284
  13. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17(10):3110–3116
  14. Russack V, Kim S, Chamberlain MC (1993) Quantitative cerebrospinal fluid cytology in patients receiving intracavitary chemotherapy. Ann Neurol 34(1):108–112
  15. Oechsle K, Lange-Brock V, Kruell A et al (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136(11):1729–1735
  16. Gwak HS, Lee CH, Yang HS et al (2011) Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis. Acta Neurochir (Wien) 153(10):1971–1978
  17. Glantz MJ, Van Horn A, Fisher R et al (2010) Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 116(8):1947–1952
  18. Bleyer WA, Fallavollita J, Robison L et al (1990) Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children’s Cancer Study Group. Pediatr Hematol Oncol 7(4):329–338
  19. Methotrexate [package insert] (2005) Bedford, OH: Bedford Laboratories
  20. Kwong YL, Yeung DY, Chan JC (2009) Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 88(3):193–201
  21. Fleischhack G, Jaehde U, Bode U (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44(1):1–31
  22. Bleyer WA, Nelson JA, Kamen BA (1997) Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol 19(6):530–532
  23. Vezmar S, Becker A, Bode U et al (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49(1–2):92–104
  24. Koh S, Nelson MD Jr, Kovanlikaya A et al (1999) Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 21(2):576–578
  25. Ozon A, Topaloglu H, Cila A et al (1994) Acute ascending myelitis and encephalopathy after intrathecal cytosine arabinoside and methotrexate in an adolescent boy with acute lymphoblastic leukemia. Brain Dev 16(3):246–248
  26. Shore T, Barnett MJ, Phillips GL (1990) Sudden neurologic death after intrathecal methotrexate. Med Pediatr Oncol 18(2):159–161
  27. Rolf N, Boehm H, Kaindl AM et al (2006) Acute ascending motoric paraplegia following intrathecal chemotherapy for treatment of acute lymphoblastic leukemia in children: case reports and review of the literature. Klin Padiatr 218(6):350–354
  28. Brugnoletti F, Morris EB, Laningham FH et al (2009) Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer 52(2):293–295
  29. Szawarski P, Chapman CS (2005) A woman who couldn’t speak: report of methotrexate neurotoxicity. Postgrad Med J 81(953):194–195
  30. Weigel R, Senn P, Weis J et al (2004) Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). Clin Neurol Neurosurg 106(2):82–87
  31. Boogerd W, vd Sande JJ, Moffie D (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277–1283
  32. Simmons ED, Somberg KA (1991) Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 67(8):2062–2065
  33. Dai MS, Ho CL, Chen YC et al (2000) Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature. Ann Hematol 79(12):696–699
  34. Bernstein ML, Sobel DB, Wimmer RS (1982) Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid. Cancer 50(5):866–868
  35. Kose F, Abali H, Sezer A et al (2009) Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate. Leuk Lymphoma 50(2):282–283
  36. Gutin PH, Green MR, Bleyer WA et al (1976) Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer 38(4):1529–1534
  37. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402
  38. Kim DY, Lee KW, Yun T et al (2003) Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33(12):608–612
  39. Hitchins RN, Bell DR, Woods RL et al (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5(10):1655–1662
  40. Cytarabine [package insert] (2008) Bedford, OH: Bedford Laboratories
  41. Hamada A, Kawaguchi T, Nakano M (2002) Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 41(10):705–718
  42. Jabbour E, Thomas D, Cortes J et al (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116(10):2290–2300
  43. DeAngelis LM, Boutros D (2005) Leptomeningeal metastasis. Cancer Invest 23(2):145–154
  44. Slevin ML, Piall EM, Aherne GW et al (1982) The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 10(Suppl 1):157–168
  45. Bekassy AN, Liliemark J, Garwicz S et al (1990) Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. Med Pediatr Oncol 18(2):136–142
  46. Slevin ML, Piall EM, Aherne GW et al (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1(9):546–551
  47. Lopez JA, Nassif E, Vannicola P et al (1985) Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 3(2):119–124
  48. DeAngelis LM, Kreis W, Chan K et al (1992) Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol 29(3):173–177
  49. DepoCyte [package insert] (2007) Bridgewater, NJ: ENZON Pharmaceuticals, Inc
  50. Phuphanich S, Maria B, Braeckman R et al (2007) A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81(2):201–208
  51. NHL: National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin’s Lymphomas. V.1.2010
  52. Jaeckle KA, Phuphanich S, Bent MJ et al (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84(2):157–163
  53. Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115(9):1892–1898
  54. Ferrario C, Davidson A, Bouganim N et al (2009) Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 20(4):792–795
  55. Colozza M, Minenza E, Gori S et al (2009) Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 63(6):1157–1159
  56. Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19(8):832–836
  57. Mir O, Ropert S, Alexandre J et al (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19(11):1978–1980
  58. Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7(9):778–780
  59. Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15(5):1373–1377
  60. Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2(3):235
  61. Mego M, Sycova-Mila Z, Obertova J et al (2011) Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 20(5):478–480
  62. Oliveira M, Braga S, Passos-Coelho JL et al (2011) Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127(3):841–844
  63. Chamberlain MC, Johnston SK, Van Horn A et al (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91(3):271–277
  64. Hong SJ, Kim JS, Chang JH et al (2009) A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 50(2):280–283
  65. Villela L, Garcia M, Caballero R et al (2008) Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs 19(9):917–920
  66. Antonini G, Cox MC, Montefusco E et al (2007) Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 81(2):197–199
  67. Billio A, Svaldi M, Morello E et al (2006) A case of relapsed meningeal Burkitt’s leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine. Am J Hematol 81(10):798–799
  68. Takami A, Hayashi T, Kita D et al (2006) Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab. Cancer Sci 97(1):80–83
  69. Schulz H, Pels H, Schmidt-Wolf I et al (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89(6):753–754
  70. Pels H, Schulz H, Manzke O et al (2002) Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 59(3):213–216
  71. Pels H, Schulz H, Schlegel U et al (2003) Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 26(4):351–354
  72. Liu CY, Teng HW, Lirng JF et al (2008) Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 49(10):2018–2021
  73. Akyuz C, Aydin GB, Cila A et al (2007) Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child. Leuk Lymphoma 48(6):1253–1255
  74. van de Glind G, de Graaf S, Klein C et al (2008) Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 50(4):886–888
  75. Gururangan S, Petros WP, Poussaint TY et al (2006) Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 12(5):1540–1546
  76. van der Gaast A, Sonneveld P, Mans DR et al (1992) Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol 29(4):335–337
  77. Penne KL (2004) Phase 1 study of intrathecal Spartaject™ Busulfan in patients with neoplastic meningitis. SoCRA Source, pp 27–29
  78. Fleischhack G, Reif S, Hasan C et al (2001) Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 84(11):1453–1459
  79. Slavc I, Schuller E, Czech T et al (1998) Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 38(2–3):213–218
  80. Slavc I, Schuller E, Falger J et al (2003) Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 64(3):239–247
  81. Groves MD, Glantz MJ, Chamberlain MC et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208–215
  82. Fisher PG, Kadan-Lottick NS, Korones DN (2002) Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 24(4):274–278
  83. Witham TF, Fukui MB, Meltzer CC et al (1999) Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 86(7):1347–1353
  84. Bernardi RJ, Bomgaars L, Fox E et al (2008) Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol 62(2):355–361
  85. Herceptin [package insert]. South San Francisco, CA: Genentech, Inc. 2010
  86. Plosker GL, Keam SJ (2006) Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66(4):449–475
  87. Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18(11):2349–2351
  88. Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18(1):23–28
  89. Rituxan [package insert] (2010) South San Francisco, CA: Genentech, Inc
  90. Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 63(8):803–843
  91. Berinstein NL, Grillo-Lopez AJ, White CA et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9(9):995–1001
  92. Petereit HF, Rubbert-Roth A (2009) Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 15(2):189–192
  93. Harjunpaa A, Wiklund T, Collan J et al (2001) Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42(4):731–738
  94. Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25(11):1350–1356
  95. Chamberlain MC, Glantz MJ (2007) Intra-CSF rituximab for lymhomatous meningitis. J Clin Oncol 25(28): 4508–4509; author reply 4509–11
  96. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O et al (2009) Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 144(5):794–795
  97. Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82(9):1756–1763
  98. Penne KL (2004) Phase 1 study of intrathecal Spartaject™ Busulfan in patients with neoplastic meningitis. SoCRA Source. 2004:27–29
  99. van Maanen JM, Retel J, de Vries J et al (1988) Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 80(19):1526–1533
  100. Etoposide [package insert] (1998) Irvine, CA: Gensia Sicor Pharmaceuticals, Inc
  101. Blaney SM, Balis FM, Berg S et al (2005) Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 23(7):1555–1563
  102. Food and Drug Administration. List of orphan drugs designated and approved as of December 31, 2003
  103. Blaney SM, Heideman R, Berg S et al (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21(1):143–147
  104. Alberts DS, Einspahr JG, Struck R et al (1984) Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs 2(2):141–148
  105. Heideman RL, Cole DE, Balis F et al (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49(3):736–741
  106. Batchelor T (2009) Leptomeningeal metastases in American Society of Clinical Oncology (ASCO 2009 annual meeting)
• 作者单位：1. Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S. Wood St. M/C 713, Chicago, IL 60612, USA2. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, USA3. University of Kentucky, 800 Rose St. CC 447, Lexington, KY 40536, USA4. HealthCare Milwaukee, Milwaukee, WI 53219, USA
• ISSN：1432-0843

文摘

Leptomeningeal carcinomatosis is a devastating complication of cancer and is likely increasing in incidence. The combination of widespread neuro-axial spread based on CSF flow and the blood–brain barrier (BBB) has favored immediate local delivery of antineoplastic agents. With the BBB, the leptomeninges can be a sanctuary site to systemic cancers and goal of therapy includes preventing involvement in this space. Current therapies with U.S. Food and Drug Administration (FDA) approval are limited to treat hematologic cancers. Although lacking FDA guidance, a wider array of therapies is available to treat solid tumors. We provide an updated examination on both well-established intra-CSF chemotherapies as well as agents having limited data, but reports of therapeutic benefit.